Evidence map›Paper›PMID 40796115›Full record

ArticleThe oncologist2025

Treatment, outcomes, and resource utilization among patients with metastatic breast and advanced epithelial ovarian cancer, by BRCA1/2 and HRD status.

Giovanna I Cruz, Kaitlyn L Kane, Rayna K Matsuno, Connor Sweetnam, Adrienne F O Williams, Liz M Toland, Amy Stone, Anna B Berry, Monika A Izano, Liam C Lee and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Giovanna I CruzInsights, Syapse Holdings, Inc., West Chester, PA, United States.ORCID 0000-0001-7422-6043
Kaitlyn L KaneInsights, Syapse Holdings, Inc., West Chester, PA, United States.
Rayna K MatsunoInsights, Syapse Holdings, Inc., West Chester, PA, United States.
Connor SweetnamInsights, Syapse Holdings, Inc., West Chester, PA, United States.
Adrienne F O WilliamsInsights, Syapse Holdings, Inc., West Chester, PA, United States.
Liz M TolandInsights, Syapse Holdings, Inc., West Chester, PA, United States.
Amy StoneInsights, Syapse Holdings, Inc., West Chester, PA, United States.
Anna B BerryInsights, Syapse Holdings, Inc., West Chester, PA, United States.
Monika A IzanoInsights, Syapse Holdings, Inc., West Chester, PA, United States.
Liam C LeeMerck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, United States.
Jagadeswara R EarlaMerck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, United States.
Thomas D BrownInsights, Syapse Holdings, Inc., West Chester, PA, United States.
Charles W DrescherSwedish Cancer Institute, Seattle, WA, United States.
Henry G KaplanSwedish Cancer Institute, Seattle, WA, United States.
Smita KothariMerck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, United States.
Arthur SillahMerck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, United States.
Gieira JonesMerck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, United States.

Funding

Merck & Co., IncMerck Sharp & Dohme Corp
6 · The paper itself

Abstract

backgroundPoly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPis) are indicated for treatment of tumors with breast cancer susceptibility genes BRCA1/2 mutations and homologous recombination deficiency (HRD). Little is known about differences in care by BRCA1/2 and HRD status for breast and ovarian cancers.

methodsWe investigated clinical characteristics, treatment, clinical outcomes, and health-care resource utilization by BRCA1/2 or HRD status among patients diagnosed between 2018-2020 with HER2-negative metastatic breast (mBC) and advanced epithelial ovarian cancer (aEOC) in the United States community healthcare setting.

resultsThe study included 314 patients with mBC and 465 with aEOC. Patients with mBC carrying a BRCA1/2 mutation were younger and had a higher proportion of triple negative cancer than non-carriers (50% vs 38%). Only 8% of eligible patients received a PARPi in first-line (1L) and 18% in second-line (2L) of treatment for mBC. In aEOC, patients with HRD were younger and a higher proportion received 1L maintenance treatment with a PARPi than patients with non-HRD tumors (95% vs 66%). In aEOC, patients without HRD had greater healthcare resource use. Patients with BRCA-mutated tumors had poorer overall survival (OS); there were no differences in OS by HRD status in aEOC.

conclusionThis study demonstrated differences in treatment by BRCA1/2 and HRD status. There was low PARPi uptake among patients with BRCA-mutated mBC but not among patients with aEOC. In aEOC, the cost to "treat all" may outweigh benefits; identifying patients without HRD likely to benefit from PARPis is needed.

Indexed as

BRCA1 ProteinBRCA2 ProteinBreast NeoplasmsCarcinoma, Ovarian EpithelialOvarian NeoplasmsAdultAgedFemaleHumansMiddle AgedMutationNeoplasm MetastasisPoly(ADP-ribose) Polymerase InhibitorsTreatment OutcomeBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanPoly(ADP-ribose) Polymerase InhibitorsBRCAbreast neoplasmscarcinomahealth resourceshomologous recombination deficiencyhospitalizationovarian epithelialsurvival analysis

Identifiers

PMID40796115
PMCPMC12342895

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.